Deborah Persaud

Last updated
Deborah Persaud
Born (1960-08-23) 23 August 1960 (age 63)
Port Mourant, East Berbice-Corentyne, British Guiana (present-day Guyana)
Known for HIVs, AIDSs
Scientific career
Fields HIV in children
InstitutionsHopkins Children's Center
Johns Hopkins University School of Medicine

Deborah Persaud (born 23 August 1960) is a Guyanese-born American virologist who primarily works on HIV/AIDS at Johns Hopkins Children's Center.

Contents

Biography

Persaud was born on 23 August 1960 in Port Mourant, East Berbice-Corentyne, Guyana to an Indo-Guyanese family. At age 16 she moved to Brooklyn. Persaud attended the New York University School of Medicine after receiving her undergraduate degree from York College CUNY. [1] She also earned a master's degree at the New York University School of Medicine. She started residency at the Babies Hospital of New York and finished her chief residency at the same hospital. Persaud later was a fellow at the New York University School of Medicine. She began her academic career as an assistant professor of pediatrics at the Johns Hopkins University School of Medicine from 1997 to 2004. In 2005, Persaud became an associate professor of pediatrics at the Johns Hopkins University School of Medicine.

Research

The main topic of Persaud's research is AIDS and HIV of children. However, her research started from research about HIV in adults. In 2003, she stated about the human immunodeficiency virus (HIV)- type1 included in the subtypes of HIV. For the HIV patient, the HAART (highly active antiretroviral therapy) is used as treatment. The HAART regimen includes some drugs containing nucleoside reverse transcriptase inhibitors (NRTIs) and protease inhibitor (PI), and non-nucleoside reverse transcriptase inhibitors (NNRTI). [2] The HAART has important function to suppress the levels of HIV-1 to below quantification. HIV-1 persists in cellular reservoirs of CD4+ continually with low-level viremia in adults, and this is very sensitive. Persaud and her research team found that viremia persists in children with plasma virus remaining at a level under the limit of detection of clinical assays. [3] When children with HIV-1 receive HAART treatment, the viremia that is difficult to observe is continued virus production without resistance in the protease gene. [4] Persaud's research team tried to find a novel culture assay that can stimulate the virus production during their latent, integrated HIV-1 in resting CD4+ T cells with the antiretroviral drugs. These drugs interfere with the replication of unintegrated virus. They also demonstrated the facts that HIV-1 polymerase sequences from the resting CD4+ T cells of the patients. [5] By following this research, her research topic has been about antiretroviral therapy. In 2009, her research team focused on the ongoing human immunodeficiency virus type 1 (HIV-1). From this research, it was figured out ongoing virus replication contributes to low-level viremia in patients on HAART, and this ongoing replication is subject to CD8+ T-cell selective pressure. After that, she suggested the induction therapy by using protease-inhibitors has influenced the effect of NNRTI (non-Nucleoside reverse transcriptase inhibitors) resistance on virologic response to nevirapine-based HAART in children patients of HIV. For a long time, her research topic has been focusing on the therapy of HIV-1 especially with the child patients. In order to develop the therapy, she has been explained about the mechanism using the NNRTI of HAART. [6]

In 2013 Persaud worked as part of a team who showed that a baby had been cured of HIV by giving it anti-HIV drugs; she won the Elizabeth Glaser Scientist Award and was featured in Time magazine's list of the 100 most influential people in 2013. [7] [8] [9] [10] She was also included in Nature's 10 for 2013, by the journal Nature . [11] In 2014 Persaud's work contributed to a second baby being cured of HIV. [12]

Professional activity

Related Research Articles

<span class="mw-page-title-main">Zidovudine</span> Antiretroviral medication

Zidovudine (ZDV), also known as azidothymidine (AZT), was the first antiretroviral medication used to prevent and treat HIV/AIDS. It is generally recommended for use in combination with other antiretrovirals. It may be used to prevent mother-to-child spread during birth or after a needlestick injury or other potential exposure. It is sold both by itself and together as lamivudine/zidovudine and abacavir/lamivudine/zidovudine. It can be used by mouth or by slow injection into a vein.

The management of HIV/AIDS normally includes the use of multiple antiretroviral drugs as a strategy to control HIV infection. There are several classes of antiretroviral agents that act on different stages of the HIV life-cycle. The use of multiple drugs that act on different viral targets is known as highly active antiretroviral therapy (HAART). HAART decreases the patient's total burden of HIV, maintains function of the immune system, and prevents opportunistic infections that often lead to death. HAART also prevents the transmission of HIV between serodiscordant same-sex and opposite-sex partners so long as the HIV-positive partner maintains an undetectable viral load.

Reverse-transcriptase inhibitors (RTIs) are a class of antiretroviral drugs used to treat HIV infection or AIDS, and in some cases hepatitis B. RTIs inhibit activity of reverse transcriptase, a viral DNA polymerase that is required for replication of HIV and other retroviruses.

<span class="mw-page-title-main">Nevirapine</span> Chemical compound

Nevirapine (NVP), sold under the brand name Viramune among others, is a medication used to treat and prevent HIV/AIDS, specifically HIV-1. It is generally recommended for use with other antiretroviral medications. It may be used to prevent mother to child spread during birth but is not recommended following other exposures. It is taken by mouth.

This is a list of AIDS-related topics, many of which were originally taken from the public domain U.S. Department of Health Glossary of HIV/AIDS-Related Terms, 4th Edition.

<span class="mw-page-title-main">Efavirenz</span> Antiretroviral medication

Efavirenz (EFV), sold under the brand names Sustiva among others, is an antiretroviral medication used to treat and prevent HIV/AIDS. It is generally recommended for use with other antiretrovirals. It may be used for prevention after a needlestick injury or other potential exposure. It is sold both by itself and in combination as efavirenz/emtricitabine/tenofovir. It is taken by mouth.

<span class="mw-page-title-main">Rega Institute for Medical Research</span> Belgian biomedical research institute

The Rega Institute for Medical Research is a Belgian scientific establishment that is part of the Catholic University of Leuven (Leuven) in central Belgium. The Rega Institute is an interfacultary biomedical research institute of the Catholic University of Leuven and consists of departments of medicine and pharmacology.

<span class="mw-page-title-main">Delavirdine</span> Chemical compound

Delavirdine (DLV) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) marketed by ViiV Healthcare. It is used as part of highly active antiretroviral therapy (HAART) for the treatment of human immunodeficiency virus (HIV) type 1. It is presented as the mesylate. The recommended dosage is 400 mg, three times a day.

<span class="mw-page-title-main">Rudi Pauwels</span> Belgian pharmacologist and entrepreneur

Rudi Pauwels is a Belgian pharmacologist and biotech entrepreneur.

<span class="mw-page-title-main">Resistance mutation (virology)</span> Virus mutation

A resistance mutation is a mutation in a virus gene that allows the virus to become resistant to treatment with a particular antiviral drug. The term was first used in the management of HIV, the first virus in which genome sequencing was routinely used to look for drug resistance. At the time of infection, a virus will infect and begin to replicate within a preliminary cell. As subsequent cells are infected, random mutations will occur in the viral genome. When these mutations begin to accumulate, antiviral methods will kill the wild type strain, but will not be able to kill one or many mutated forms of the original virus. At this point a resistance mutation has occurred because the new strain of virus is now resistant to the antiviral treatment that would have killed the original virus. Resistance mutations are evident and widely studied in HIV due to its high rate of mutation and prevalence in the general population. Resistance mutation is now studied in bacteriology and parasitology.

<span class="mw-page-title-main">Etravirine</span> Also called Intelence is a drug used for the treatment of HIV

Etravirine is a drug used for the treatment of HIV. Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI). Unlike the currently available agents in the class, resistance to other NNRTIs does not seem to confer resistance to etravirine. Etravirine is marketed by Janssen, a subsidiary of Johnson & Johnson. In January 2008, the Food and Drug Administration approved its use for patients with established resistance to other drugs, making it the 30th anti-HIV drug approved in the United States and the first to be approved in 2008. It was also approved for use in Canada on April 1, 2008.

<span class="mw-page-title-main">Rilpivirine</span> HIV treatment

Rilpivirine, sold under the brand names Edurant and Rekambys, is a medication, developed by Tibotec, used for the treatment of HIV/AIDS. It is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) with higher potency, longer half-life and reduced side-effect profile compared with older NNRTIs such as efavirenz.

<span class="mw-page-title-main">HIV disease–related drug reaction</span>

HIV disease–related drug reaction is an adverse drug reaction caused by drugs used for the treatment of HIV/AIDS.

Non-nucleoside reverse-transcriptase inhibitors (NNRTIs) are antiretroviral drugs used in the treatment of human immunodeficiency virus (HIV). NNRTIs inhibit reverse transcriptase (RT), an enzyme that controls the replication of the genetic material of HIV. RT is one of the most popular targets in the field of antiretroviral drug development.

Stuart C. Ray is an American physician. He is Vice Chair of Medicine for Data Integrity and Analytics, Associate Director of the Infectious Diseases Fellowship Training Program at the Johns Hopkins School of Medicine, and a Professor in the Department of Medicine, Division of Infectious Diseases. Ray also holds appointments in Viral Oncology and the Division of Health Sciences Informatics. He is affiliated with the Institute for Computational Medicine at Johns Hopkins and is licensed to practice medicine in Maryland.

Discovery and development of nucleoside and nucleotide reverse-transcriptase inhibitors began in the 1980s when the AIDS epidemic hit Western societies. NRTIs inhibit the reverse transcriptase (RT), an enzyme that controls the replication of the genetic material of the human immunodeficiency virus (HIV). The first NRTI was zidovudine, approved by the U.S. Food and Drug Administration (FDA) in 1987, which was the first step towards treatment of HIV. Six NRTI agents and one NtRTI have followed. The NRTIs and the NtRTI are analogues of endogenous 2´-deoxy-nucleoside and nucleotide. Drug-resistant viruses are an inevitable consequence of prolonged exposure of HIV-1 to anti-HIV drugs.

Julio S. G. Montaner, is an Argentine-born Canadian physician, professor and researcher. He is the director of the British Columbia Centre for Excellence in HIV/AIDS, the chair in AIDS Research and head of the Division of AIDS in the Faculty of Medicine at the University of British Columbia and the past-president of the International AIDS Society. He is also the director of the John Ruedy Immunodeficiency Clinic, and the Physician Program Director for HIV/AIDS PHC. He is known for his work on HAART, a role in the discovery of triple therapy as an effective treatment for HIV in the late 1990s, and a role in advocating the "Treatment as Prevention" Strategy in the mid-2000s, led by Myron Cohen of the HPTN 052 trial.

Viral load monitoring for HIV is the regular measurement of the viral load of individual HIV-positive people as part of their personal plan for treatment of HIV/AIDS. A count of the viral load is routine before the start of HIV treatment.

<span class="mw-page-title-main">Bictegravir/emtricitabine/tenofovir alafenamide</span> Fixed dose combination HIV drug

Bictegravir/emtricitabine/tenofovir alafenamide, sold under the brand name Biktarvy, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS. It contains bictegravir, a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor; emtricitabine, an HIV-1 nucleoside analog reverse transcriptase inhibitor; and tenofovir alafenamide, an HIV-1 nucleoside analog reverse transcriptase inhibitor.

<span class="mw-page-title-main">Cabotegravir/rilpivirine</span> Co-packaged antiretroviral medication

Cabotegravir/rilpivirine, sold under the brand name Cabenuva, is a co-packaged antiretroviral medication for the treatment of HIV/AIDS. It contains cabotegravir and rilpivirine in a package with two separate injection vials.

References

  1. ↑ Swingle, Anne (May 2005). "Deborah Persaud: Clinician First, Scientist Second". Dome: News for the Johns Hopkins Medicine Family. 56 (4). Archived from the original on 2014-12-04.
  2. ↑ Chichocki, Mark (3 June 2014). "HAART-Highly Active Antiretroviral Therapy". About health. Archived from the original on 11 July 2014. Retrieved 3 June 2014.
  3. ↑ Persaud, Deborah (2003). "Latency in human immunodeficiency virus type 1 infection: No easy answers". Journal of Virology. 77 (3): 1659–1665. doi:10.1128/jvi.77.3.1659-1665.2003. PMC   140995 . PMID   12525599.
  4. ↑ Kieffer, Tara; Finucane, Mariel; Nettles, Richard (2004). "Genotypic analysis of HIV-1 drug resistance at the limit of detection: Virus production without evolution in treated adults with undetectable HIV loads". Journal of Infectious Diseases. 189 (8): 1452–1465. doi: 10.1086/382488 . PMID   15073683.
  5. ↑ Nettles, Richard; Kieffer, Tara; Simmons, Rachel; Cofrancesco, Joseph; Moore, Richard; Gallant, Joel; Persaud, Deborah; Siliciano, Robert (2004). "Genotypic resistance in HIV-1 infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy". Clinical Infectious Diseases. 39 (7): 1030–1037. doi: 10.1086/423388 . PMID   15472857.
  6. ↑ Shiuu, Carlum; Cunningham, Coleen; Greenough, Thomas; Muresan, Petronella; Sanchez-Merino, Victor; Carey, Vincent; Jackson, J.Brooks; Ziemniak, Carrie; Fox, Lawrence; Belzer, Marvin (2009). "Identification of ongoing human immunodeficiency virus type 1 (HIV-1) replication in residual viremia during recombinant HIV-1 poxvirus immunizations in patients with clinically undetectable viral loads on durable suppressive highly active antiretroviral therapy". Journal of Virology. 83 (19): 9731–9742. doi:10.1128/jvi.00570-09. PMC   2748010 . PMID   19605490.
  7. ↑ Clarke, Tangerine (14 March 2013). "Deborah Persaud wins award for AIDS research". Caribbean Life. Retrieved 23 March 2014.
  8. ↑ Pappas, Stephanie (18 December 2013). "These 10 scientists pushed boundaries and made breakthroughs in 2013". Mother Nature Network. Retrieved 23 March 2014.
  9. ↑ Dybul, Mark (18 April 2013). "The 2013 Time 100: Hannah Gay, Katherine Luzuriaga and Deborah Persaud". Time . Retrieved 23 March 2014.
  10. ↑ "Time Magazine Names Johns Hopkins Pediatric HIV Expert Deborah Persaud to 2013 World List of 'Top 100' Influential People". Johns Hopkins Children's Center. Archived from the original on April 27, 2013. Retrieved 18 April 2013.
  11. ↑ Alex Jackson (19 December 2013). "Nature's 10 people who mattered in 2013". Nature.com. Archived from the original on 23 December 2019. Retrieved 14 February 2020.
  12. ↑ McNeil, Donald (5 March 2014). "Early Treatment Is Found to Clear H.I.V. in a 2nd Baby". The New York Times . Retrieved 23 March 2014.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.